Research on multiple myeloma (MM) discovered that human osteoclast precursors expressed BDNF receptor TrkB and a Trk inhibitor, K252a, significantly decreased BDNF-stimulated osteoclast production, suggesting that BDNF utilized TrkB for its influence on osteoclasts. The gene discussed is NTRK2; the disease is Miyoshi myopathy.